Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age

NCT05819775 is registered in ClinicalTrials.gov with CSL Behring as lead sponsor.

NCT NCT05819775
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05819775 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age
Lead sponsor
CSL Behring
Phase
Phase 3
Overall status
Completed
Start date
May 30, 2023
Completion date
November 19, 2025
Enrollment
22 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary angioedema (hae)